Improving early cycle economic evaluation of diagnostic technologies

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 14, Issue 4, 2014, Pages 491-498

  Steuten, Lotte Mg ^a   Ramsey, Scott D ^b  

^a UNIVERSITY OF TWENTE   (Netherlands)

^b USA   (United States)

Author keywords

Decision makers; Diagnostics; Economic evaluation; Value of information

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CLINICAL EFFECTIVENESS; DECISION TREE; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EARLY CYCLE ECONOMIC EVALUATION; ECONOMIC EVALUATION; GENETIC SCREENING; HEALTH CARE COST; INVESTMENT; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; MOLECULAR DIAGNOSTICS; PRODUCT DEVELOPMENT; REVIEW; DECISION MAKING; DECISION SUPPORT SYSTEM; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; TIME;

DECISION MAKING; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMANS; TIME FACTORS;

EID: 84904364481     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2014.914435     Document Type: Review

References (34)

1. Smith-Bindman R, Miglioretti DL, Johnson E. Use of diagnostic imaging studies and associated radiation exposure for patients enrolled in large integrated. health care systems, 1996-2010. JAMA 2012; 307(22):2400-9
2. Report to congressional requesters: Medicare Part B imaging services: Rapid spending growth and shift to physician offices indicated need for CMS to consider additional management practices [GAO-08-452]. Government Accountability Office. Available from: Www.gao.gov/new.items/ d08452.pdf [Last accessed 8 December 2013]
3. Organisation of Economic Co-operation and Development: OECD StatExtracts, Health Care Utilization, Diagnostic Exams. Available from: Http://stats.oecd. org/# [Last accessed 8 December 2013]
4. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd edition. Oxford University Press; Oxford, UK: 2005
5. Guyatt GH, Tugwell PX, Feeney DH, et al. A framework for clinical evaluation of diagnostic technologies. CMAJ 1986;134: 587-94
6. European Network for Health Technology Assessment (EUNetHTA). HTA Core Model for diagnostic technologies. Available from: Www.eunethta.eu/outputs/hta- coremodel-diagnostic-Technologies-10r [Last accessed 8 December 2013]
7. International Society Pharmacoeconomics Outcomes Research (ISPOR). Good practices for outcomes research. Available from: Www.ispor.org/workpaper/ practices-index.asp [Last accessed 8 December 2013]
8. Severens JL, van der Wilt GJ. Economic evaluation of diagnostic tests. A review of published studies. Int J Technol Assess Health Care 1999;15(3):480-96
9. IJzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: A review of methods and applications. Appl Health Econ Health Policy 2011;9(5):331-47
10. Van de Wetering G, Steuten LMG, Von Birgelen C, et al. Early Bayesian modeling of a potassium lab-on-A-chip for monitoring of heart failure patients at increased risk of hyperkalemia. Technol Forecast Soc Change 2012;79(7):1268-79
11. Vallejo-Torres L, Steuten LMG, Girling A, et al. Integrating health economics modeling in the product development cycle of medical devices: A Bayesian approach. Int J Technol Assess Health Care 2008;24(4):459-64
12. Vallejo-Torres L, Steuten L, Parkinson B, et al. Integrating health economics into the product development cycle: A case study of absorbable pins for treating hallux valgus. Med Decis Making 2011;31(4):596-610
13. Pepe MS, Etzioni R, Feng Z, et al. Phases of Biomarker Development for Early Detection of Cancer. J Natl Cancer Inst 2001;93(14):1054-61
14. Steuten LMG, Van de Wetering G, Groothuis-Oudshoorn C, Retel VP. Systematic and critical review of the evolving methods and applications of value of information research in academia and practice. Pharmacoeconomics 2013;31(1): 25-48
15. Sculpher M, Drummond M, Buxton MJ. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 1997;2:26-30
16. Cosh E, Girling A, Lilford R, et al. Investing in new medical technologies: A decision framework. J Commerc Biotechnol 2007;13:263-71
17. Lee CI, Bensink ME, Berry K, et al. Performance goals for an adjunct diagnostic test to reduce unnecessary biopsies after screening mammography: Analysis of costs, benefits, and consequences. J Am Coll Radiol 2013;10(12):924-30
18. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ 2007;16(2):195-209
19. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360(9334): 711-15
20. Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Methods in health service research: An introduction to Bayesian methods in health technology assessment. BMJ 1999;319:508-12
21. Carlson JJ, Thariani R, Roth J, et al. Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: An application in cancer genomics. Med Decis Making 2013; 33(4):463-71
22. Sculpher M, Claxton K, Drummond M, McCabe C. Whither trial-based economic evaluation for health care decision making? Health Econ 2006;15:677-87
23. Wong W, Ramsey SD, Barlow WE, et al. The value of comparative effectiveness research: Projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials 2012;33:1117-23
24. Ramsey SD, Barlow WE, Gonzalez-Angulo AM, et al. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemp Clin Trials 2013; 34(1):1-9
25. Hiance A, Chevret S, Levy V. A practical approach for eliciting expert prior beliefs about cancer survival in phase III randomized trial. J Clin Epidemiol 2009; 62(4):431-7
26. Johnson SR, Tomlinson GA, Hawker GA, et al. A valid and reliable belief elicitation method for Bayesian priors. J Clin Epidemiol 2010;63(4):370-83
27. Leal J, Wordsworth S, Legood R, Blair E. Eliciting expert opinion for economic models: An applied example. Value Health 2007;10(3):195-203
28. Bojke L, Claxton K, Bravo-Vergel Y, et al. Eliciting distributions to populate decision analytic models. Value Health 2010;13(5): 557-64
29. Soares MO, Bojke L, Dumville J, et al. Methods to elicit experts' beliefs over uncertain quantities: Application to a cost effectiveness transition model of negative pressure wound therapy for severe pressure ulceration. Stat Med 2011;30(19):2363-80
30. Hammitt JK, Shlyakhter AI. The expected value of information and the probability of surprise. Risk Anal 1999;19(1):135-52
31. Hammitt JK. Can more information increase uncertainty? Chance 1995;8(3): 15-17
32. Ramsey SD, Blough DK, Sullivan SD. A forensic evaluation of the national emphysema treatment trial using the expected value of information approach. Med Care 2008;46(5):542-8
33. Brennan A, Kharroubi SA. Efficient computation of partial expected value of sample information using Bayesian approximation. J Health Econ 2007;26(1): 122-48
34. Eckermann S, Karnon J, Willan AR. The value of value of information. Pharmacoeconomics 2010;28(9):699-709.